Avalo Therapeutics, Inc. Common Stock

AVTXNASDAQUSD
13.10 USD
0.51 (3.75%)AT CLOSE (11:59 AM EDT)
13.08
0.02 (0.12%)
POST MARKET (AS OF 07:36 PM EDT)
Post Market
AS OF 07:36 PM EDT
13.08
0.02 (0.12%)
🔴Market: CLOSED
Open?$13.62
High?$13.76
Low?$12.89
Prev. Close?$13.61
Volume?1.8M
Avg. Volume?2.3M
VWAP?$13.22
Rel. Volume?0.75x
Bid / Ask
Bid?$12.90 × 100
Ask?$15.60 × 100
Spread?$2.70
Midpoint?$14.25
Valuation & Ratios
Market Cap?688.6M
Shares Out?52.6M
Float?21.2M
Float %?86.6%
P/E Ratio?N/A
P/B Ratio?10.08
EPS?-$1.61
Dividend?0.00%
Ex-Dividend?N/A

Shares of Avalo Therapeutics, Inc. Common Stock (AVTX) are trading at $13.10. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Employees
33
Market Cap
688.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-11-13
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
97
Momentum?
23
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?4.84Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?29.47%Squeeze Risk
Short Interest?6.3M
Days to Cover?1.6
Free Float21.2M
Avg Daily Volume3.9M
Settlement Date2026-05-15
Financial Health
Current Ratio?7.65Strong
Quick Ratio?7.65Strong
Cash Ratio?2.15Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A
P/B?
Peers
100
S&P
19
10.08HIGH
P/S?
Peers
100
S&P
3
11,671.34HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-8.4CHEAP
EV/Sales?
Peers
100
S&P
3
11,247.81HIGH
Returns & Efficiency
ROE?
S&P
3
-124.0%WEAK
ROA?
S&P
3
-84.8%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$663.6M
Fundamentals ratios updated end of day